文献速递脊柱关节炎类风湿关节炎

早期银屑病关节炎与类风湿关节炎甲氨蝶呤治疗的比较:一项观察性全国性研究

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study.
PubMed 文献 · RMD Open · 2023-01-01

基于瑞典全国登记数据,将2011-2019年新诊断且未用过DMARD的银屑病关节炎(PsA)患者与类风湿关节炎(RA)患者按1:1匹配,比较起始甲氨蝶呤后2年内继续用药及未启用其他DMARD的比例,并评估6个月疗效。两组甲氨蝶呤留存与启用其他DMARD情况相似,但RA组6个月疾病活动度改善优于PsA组。

要点

  • 起始甲氨蝶呤2年后,PsA组71% vs RA组76%仍在用甲氨蝶呤,66% vs 60%未启用其他DMARD。
  • 6个月时PsA组达到疼痛评分≤15 mm者26% vs RA组36%,校正OR为0.63(95%CI 0.47-0.85)。
  • 6个月时PsA组达到评估者判定「缓解」者20% vs RA组27%,校正OR为0.54(95%CI 0.39-0.75)。

核心结论

  • 在瑞典临床实践中,PsA与RA的甲氨蝶呤使用情况相似,包括启用其他DMARD和甲氨蝶呤留存。
  • 组水平上,两种疾病在甲氨蝶呤单药治疗期间疾病活动度均改善,但RA改善更多。

研究设计与样本

  • 观察性全国性研究,从瑞典高质量全国登记中识别2011-2019年起始甲氨蝶呤的新诊断、未用过DMARD的PsA患者,与可比的RA患者按1:1匹配。
  • 共纳入3642/3642例PsA/RA患者;对基线和6个月有疾病活动度数据的患者,采用逻辑回归比较甲氨蝶呤单药治疗反应,并应用无应答者填补。

主要发现

  • 基线时两组患者报告疼痛和总体健康相似,而RA组28关节评分和评估者判定的疾病活动度更高。
  • 起始甲氨蝶呤2年后,PsA组71% vs RA组76%仍在用甲氨蝶呤,66% vs 60%未启用其他DMARD,77% vs 74%未启用生物或靶向合成DMARD。
  • 6个月时,PsA组 vs RA组达到疼痛评分≤15 mm者26% vs 36%,达到总体健康≤20 mm者32% vs 42%,达到评估者判定「缓解」者20% vs 27%。
  • 6个月时PsA vs RA的校正OR分别为:疼痛评分≤15 mm 0.63(95%CI 0.47-0.85)、总体健康≤20 mm 0.57(95%CI 0.42-0.76)、评估者判定「缓解」0.54(95%CI 0.39-0.75)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We aimed to compare the proportions of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) remaining on methotrexate (regardless of other disease-modifying antirheumatic drug (DMARD)-changes), and proportions not having started another DMARD (regardless of methotrexate discontinuation), within 2 years of starting methotrexate, as well as methotrexate effectiveness. METHODS: Patients with DMARD-naïve, newly diagnosed PsA, starting methotrexate 2011-2019, were identified from high-quality national Swedish registers and matched 1:1 to comparable patients with RA. Proportions remaining on methotrexate and not starting another DMARD were calculated. For patients with disease activity data at baseline and 6 months, response to methotrexate monotherapy was compared through logistic regression, applying non-responder imputation. RESULTS: In total, 3642/3642 patients with PsA/RA were included. Baseline patient-reported pain and global health were similar, whereas patients with RA had higher 28-joint scores and evaluator-assessed disease activity. Two years after methotrexate start, 71% of PsA vs 76% of patients with RA remained on methotrexate, 66% vs 60% had not started any other DMARD, and 77% vs 74% had not started specifically a biological or targeted synthetic DMARD. At 6 months, the proportions of patients with PsA versus RA achieving pain-scores ≤15 mm were 26% vs 36%; global health ≤20 mm: 32% vs 42%; evaluator-assessed 'remission': 20% vs 27%, with corresponding adjusted ORs (PsA vs RA) of 0.63 (95% CI 0.47 to 0.85); 0.57 (95% CI 0.42 to 0.76) and 0.54 (95% CI 0.39 to 0.75). DISCUSSION: In Swedish clinical practice, methotrexate use is similar in PsA and RA, both regarding initiation of other DMARDs and methotrexate retention. On a group level, disease activity improved during methotrexate monotherapy in both diseases, although more so in RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lindström U, di Giuseppe D, Exarchou S, et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study. RMD Open. 2023. PMID: 37173095. doi:10.1136/rmdopen-2022-002883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。